Payandeh Mehrdad, Shahriari-Ahmadi Ali, Sadeghi Masoud, Sadeghi Edris
Cancer Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran E-mail :
Asian Pac J Cancer Prev. 2016;17(3):1015-8. doi: 10.7314/apjcp.2016.17.3.1015.
Overexpression or amplification of human epidermal growth factor receptor-2 (HER2) is associated with grade of malignancy and a poor prognosis in breast cancer (BC). The aim of this study was to evaluate of value of HER2 as a prognostic marker, and to analyze associations with common histopathological parameters in BC cases.
Between of 2007 to 2014, 260 patients with BC referred to Oncology Clinic provided cancer tissue samples which underwent immunohistochemistry (IHC) for markers. ER and PR positivity was defined as ≥10% positive tumor cells with nuclear staining. HER2-positive was defined as either HER2 gene amplification by fluorescent in situ hybridization (FISH) or scored as 3+ by IHC. For HER2 (2+), FISH was performed to determine HER2 positivity.
The mean age at diagnosis for the patients with HER2-negative was significantly higher than in HER2-positive cases. Also, there were significant correlations between histological grade, nuclear grade, lymph node metastasis, tumor size, ER status, PR status, p53 overexpression and Ki-67 index with HER2 expression. HER2-negative lesions were of higher grade and more likely to be ER-negative, PR-negative, p53-positive, lymph node metastasis, with a tumor size<2cm and also Ki-67≥20% as compared to the HER2-positive group.
Contrary to the results of other studies, HER2-positive tumors in our study had a lower Ki-67 index and were p53-positive. Also, Ki-67 proliferation index ≥20% in more studies was associated with p53-positive.Therefore, tumors which are HER2-positive and have a Ki-67≥20% had a more aggressive behavior compared to HER2-positive and Ki-67<20% lesions.
人表皮生长因子受体2(HER2)的过表达或扩增与乳腺癌(BC)的恶性程度及不良预后相关。本研究旨在评估HER2作为预后标志物的价值,并分析其与BC病例常见组织病理学参数的相关性。
2007年至2014年间,260例转诊至肿瘤诊所的BC患者提供了癌组织样本,这些样本接受了标志物的免疫组织化学(IHC)检测。雌激素受体(ER)和孕激素受体(PR)阳性定义为核染色阳性肿瘤细胞≥10%。HER2阳性定义为通过荧光原位杂交(FISH)检测HER2基因扩增或IHC评分为3+。对于HER2(2+),进行FISH检测以确定HER2阳性。
HER2阴性患者的诊断时平均年龄显著高于HER2阳性病例。此外,组织学分级、核分级、淋巴结转移、肿瘤大小、ER状态、PR状态、p53过表达和Ki-67指数与HER2表达之间存在显著相关性。与HER2阳性组相比,HER2阴性病变分级更高,更可能为ER阴性、PR阴性、p53阳性、有淋巴结转移,肿瘤大小<2cm且Ki-67≥20%。
与其他研究结果相反,本研究中HER2阳性肿瘤的Ki-67指数较低且p53阳性。此外,在更多研究中Ki-67增殖指数≥20%与p53阳性相关。因此,与HER2阳性且Ki-67<20%的病变相比,HER2阳性且Ki-67≥20%的肿瘤行为更具侵袭性。